Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive crawled time : 20:00 save search
Nasdaq Announces End of Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date March 28, 2024
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
NDAQ | $60.075 0.11% 0.11% 2.3M
|
Finance
|
| O: -1.16%
H: 1.24%
C: 0.3%
nasdaq
Chart Industries Credit Rating Outlook Changed to “Positive” at Moody’s
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
GTLS | $148.57 0.66% 0.0% 450K
|
Producer Manufacturing
|
| O: -1.13%
H: 1.74%
C: 1.65%
Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study
Published: 2024-04-08 (Crawled : 20:00) - globenewswire.com
SWAV | $327.42 -0.02% -0.02% 1.2M
|
Health Technology
|
| O: 0.05%
H: 0.54%
C: 0.49%
positive results study
Parsons Awarded Position on $1B NNSA Counter Nuclear Smuggling System Deployment Contract
Published: 2024-04-03 (Crawled : 20:00) - globenewswire.com
PSN | News | $77.8 -0.97% 0.0% 610K
|
Technology Services
|
| O: 1.09%
H: 0.55%
C: -0.38%
nuclear contract system
OneMedNet Completes Securities Purchase Agreement, Solidifying Cash Position to Accelerate Growth
Published: 2024-04-02 (Crawled : 20:00) - globenewswire.com
ONMD | $0.6399 3.21% 3.11% 70K
|
n/a
|
| O: 10.69%
H: 24.6%
C: 21.17%
growth
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Published: 2024-04-01 (Crawled : 20:00) - globenewswire.com
GRTS | $0.7446 -0.08% -0.08% 2.1M
|
Health Technology
|
| O: -48.62%
H: 5.38%
C: -7.69%
positive cancer ongoing tumor dna study
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
Published: 2024-03-21 (Crawled : 20:00) - biospace.com/
LUCD | $0.7957 -0.8% -0.8% 70K
|
|
| O: -0.9%
H: 8.18%
C: 0.91%
PAVM | $1.95 -1.02% -1.03% 32K
|
Health Technology
|
| O: 0.45%
H: 5.41%
C: -4.5%
esoguard first positive diagnostics study
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
Published: 2024-03-18 (Crawled : 20:00) - globenewswire.com
IVA | $3.28 1.86% 1.83% 12K
|
Health Technology
|
| O: -9.4%
H: 0.0%
C: -12.66%
positive results study
High Tide Reports First Quarter 2024 Financial Results Featuring Record Revenue, Record Adjusted EBITDA, and Third Consecutive Quarter of Positive Free Cash Flow as well as Break-Even Net Income
Published: 2024-03-15 (Crawled : 20:00) - hightideinc.com
HITI | $2.21 -1.34% -1.36% 480K
|
Manufacturing
| Email alert
Add to watchlist
first free positive flow financial results
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
Published: 2024-03-12 (Crawled : 20:00) - globenewswire.com
CRNX | $43.005 -2.28% -2.34% 540K
|
Health Technology
|
| O: 0.81%
H: 2.03%
C: -1.41%
positive treatment topline trial results
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
Published: 2024-02-22 (Crawled : 20:00) - globenewswire.com
COGT | $6.605 1.15% 1.14% 1.1M
|
Health Technology
|
| O: -1.12%
H: 0.45%
C: -15.93%
bezuclastinib positive trial
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
Published: 2024-01-16 (Crawled : 20:00) - prnewswire.com
SRPT | $116.59 -1.1% -1.12% 500K
|
Health Technology
|
| O: -0.49%
H: 3.17%
C: 1.94%
RGNX | $16.08 -5.58% -5.91% 560K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -7.15%
CLSD | $1.32 4.76% 4.55% 330K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.94%
rgx-314 aaviate positive treatment trial
Lyndra Therapeutics Announces Positive Data from Pivotal Phase 3 Study with Oral Weekly Risperidone (LYN-005) for Schizophrenia
Published: 2024-01-04 (Crawled : 20:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.37%
H: 1.38%
C: 0.82%
lyn-005 positive schizophrenia therapeutics study
Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
Published: 2024-01-02 (Crawled : 20:00) - biospace.com/
LBPH | $18.01 5.94% 5.61% 500K
|
Manufacturing
|
| O: 206.47%
H: 39.72%
C: 35.82%
lp352 positive pharmaceuticals topline
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
Published: 2023-12-11 (Crawled : 20:00) - biospace.com/
ATRA | $0.6917 -3.25% -3.35% 830K
|
Health Technology
|
| O: -7.38%
H: 7.89%
C: 6.31%
ata3431 positive preclinical meeting
Unum Group receives credit ratings upgrades from Fitch Ratings based on strong financial position
Published: 2023-11-28 (Crawled : 20:00) - prnewswire.com
UNM A | $50.79 1.26% 0.0% 920K
|
Finance
|
| O: 0.28%
H: 0.4%
C: 0.17%
group financial
Continuous positive airway pressure (CPAP) market in US to grow by USD 428.84 million from 2023 to 2028; Rising demand for home-care settings is the primary trend shaping market growth - Technavio
Published: 2023-11-17 (Crawled : 20:00) - prnewswire.com
PHG | $19.98 -0.84% 0.0% 500K
|
Health Technology
| Email alert
Add to watchlist
MDT | $79.19 0.14% 0.0% 6.1M
|
Health Technology
| Email alert
Add to watchlist
RMD | $177.61 2.18% 0.0% 1.6M
|
Health Technology
| Email alert
Add to watchlist
positive growth market
Fortinet Sharpens Business Focus on Core Growth Areas to Extend Leadership Position and Drive Continued Innovation in Cybersecurity
Published: 2023-11-02 (Crawled : 20:00) - globenewswire.com
FTNT | News M | $63.995 -1.03% -1.04% 3.1M
|
Electronic Technology
|
| O: -22.73%
H: 13.64%
C: 13.44%
business innovation cybersecurity growth
Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study
Published: 2023-11-02 (Crawled : 20:00) - globenewswire.com
KRON | $1.01 -2.89% -2.97% 210K
|
Health Technology
|
| O: 5.0%
H: 19.05%
C: 9.52%
kb-0742 positive study
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC
Published: 2023-11-01 (Crawled : 20:00) - globenewswire.com
FDMT | News | $24.71 -2.33% -2.39% 420K
|
Health Technology
|
| O: 1.4%
H: 0.13%
C: -0.55%
positive fibrosis trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.